FDA Inks $49.9 Million Deal with SAS

Published on: 

SAS will extend a 40-year partnership with the US Food and Drug Administration (FDA) to expand its capabilities in natural language processing, artificial intelligence, and machine learning capabilities through the SAS Viya platform. Through a five-year, $49.9 million Blanket Purchase Agreement, SAS will support digital transformation efforts underway in the FDA.

The initial projects will be with the FDA’s Center for Drug Evaluation and Research. Through the SAS partnership, the FDA will:

  • Advance CDER’s initiative to modernize drug regulatory programs.
  • Provide analytically driven drug manufacturing facility surveillance.
  • Better fulfill the center’s mission through other key initiatives.

For more on this deal, click here.